Cargando…
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent progn...
Autores principales: | Goncalves, Anthony, Finetti, Pascal, Birnbaum, Daniel, Bertucci, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099860/ https://www.ncbi.nlm.nih.gov/pubmed/33953185 http://dx.doi.org/10.1038/s41523-021-00256-2 |
Ejemplares similares
-
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022) -
The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020) -
The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015) -
A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019) -
The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms
por: Lesluyes, Tom, et al.
Publicado: (2017)